Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F et al (2017) GBD 2016 Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1211–59

Article  Google Scholar 

Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C (2015) Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33(29):3235–3242

Article  CAS  PubMed  PubMed Central  Google Scholar 

Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA et al (2014) Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol 25(7):1410–1416

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127

Article  CAS  PubMed  Google Scholar 

Zang X (2018) 2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade – a personal account. Genes Dis 5(4):302–303

Article  PubMed  PubMed Central  Google Scholar 

Sundar R, Cho B, Brahmer JR, Soo AR (2015) Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 7(2):85–96

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J et al (2018) Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement. Clin Cancer Res 24(14):3282–3291

Article  CAS  PubMed  PubMed Central  Google Scholar 

Facchinetti F, Bordi P, Leonetti A, Buti S, Tiseo M (2018) Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Drug Des Devel Ther 12:2857–2873

Article  CAS  PubMed  PubMed Central  Google Scholar 

Onyshchenko M (2018) The puzzle of predicting response to immune checkpoint blockade. EBioMedicine 33:18–19

Article  PubMed  PubMed Central  Google Scholar 

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909–915

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bailly C, Thuru X, Quesnel B (2020) Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer 2(1):zcaa002. https://doi.org/10.1093/narcan/zcaa002

Article  PubMed  PubMed Central  Google Scholar 

Revannasiddaiah S, Madabhavi I, Bodh A, Thakur P, Sharma M (2015) Metronomic chemotherapy in anaplastic thyroid carcinoma: a potentially feasible alternative to therapeutic nihilism. Indian J Palliat Care 21(2):245–249

Article  PubMed  PubMed Central  Google Scholar 

Revannasiddaiah S, Pandey KC, Madabhavi IV et al (2019) Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies. Ann Oncol 30(suppl_9):ix118–ix121. https://doi.org/10.1093/annonc/mdz430

Article  Google Scholar 

Madabhavi IV, Sarkar M, Sagar R (2021) Metronomic low-dose capecitabine in metastatic, recurrent, or persistent carcinoma of the cervix as 3rd line and beyond. Ann Oncol 32(suppl_5):S725–S772. https://doi.org/10.1016/annonc/annonc703

Article  Google Scholar 

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359(11):1116–27

Article  CAS  PubMed  Google Scholar 

Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56–61

Article  CAS  PubMed  Google Scholar 

Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–461

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867

Article  PubMed  PubMed Central  Google Scholar 

Zandberg DP, Strome SE (2014) The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 50(7):627–632

Article  CAS  PubMed  Google Scholar 

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

Article  PubMed  Google Scholar 

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and checkMate 057). J Clin Oncol 35:3924–3933

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833

Article  CAS  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092

Article  CAS  PubMed  Google Scholar 

Cramer JD, Burtness B, Ferris RL (2019) Immunotherapy for head and neck cancer: recent advances and future directions. Oral Oncol 99:104460

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gupta VG, Bakhshi S (2017) Pediatric hematopoietic stem cell transplantation in India: status, challenges and the way forward: Based on Dr. K. C. Chaudhuri oration 2016. Indian J Pediatr 84:36–41

Article  PubMed  Google Scholar 

Maiti R (2014) Metronomic chemotherapy. J Pharmacol Pharmacother 5(3):186–192

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nai-Wen Su, Chen Y-J (2021) Metronomic therapy in oral squamous cell carcinoma. J Clin Med 10(13):2818

Article  Google Scholar 

Patil Vijay Maruti, Noronha Vanita, Menon Nandini, Rai Rahul, Bhattacharjee Atanu, Singh Ajay et al (2023) Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol 41(2):222–23

Article  CAS  PubMed  Google Scholar 

Iqbal H (2016) Quintin Pan; Capecitabine for treating head and neck cancer. Expert Opin Investig Drugs 25(7):851–859

Article  CAS  PubMed  Google Scholar 

Van Der Kraak L, Goel G, Ramanan K, Kaltenmeier C, Zhang L, Normolle DP et al (2016) 5-Fluorouracil up-regulates cell surface B7–H1 (PD-L1) expression in gastrointestinal cancer. J Immunother Cancer 4:65

Article  PubMed  Google Scholar 

Chen YL, Chang MC, Cheng WF (2017) Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett 400:282–292

Article  CAS  PubMed  Google Scholar 

Kareva I (2017) A combination of immune checkpoint inhibition with metronomic chemotherapy as a way of targeting therapy-resistant cancer cells. Int J Mol Sci 18:2134

Article  PubMed  PubMed Central  Google Scholar 

Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229–1241

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mpekris F, Voutouri C, Panagi M, Baish JW, Jain RK, Stylianopoulos T (2022) Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy. J Control Release 345:190–199

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aravind S, Jose J, Shenoy PK, Avaronnan M, Thavarool SB, Nayanar SK (2022) The spectrum of histomorphological changes and pathological tumor response following preoperative oral metronomic chemotherapy in oral squamous cell carcinoma South Asian J. Cancer 11(2):146–151